Previous
Mendus business update and outlook for vididencel program
Mendus held a business update and outlook for the development of its lead product vididencel in acute myeloid leukemia (AML) during a live investor event on March 12, 15.00-17.00 CET.
The replay of the event is accessible via the link below.